Astridbio Technologies Research and Development Ltd. is a privately owned Hungarian biotechnology SME founded in 2011 and headquartered in Szeged, Hungary. Originally established as a bioinformatics start-up with Hungarian and Canadian operations, the company has evolved into a multidisciplinary biotech enterprise specializing in genomics, cell biology, and diagnostic innovation. Through strategic expansion, Astridbio developed expertise in 3D cancer models, targeted preamplification, and long-read next-generation sequencing technologies. The company has contributed to international research collaborations focused on cancer diagnostics and therapy prediction, while developing advanced analytical approaches for studying cancer and immune cell behavior. Certified as an Oxford Nanopore Technologies service provider, Astridbio delivers state-of-the-art sequencing and genomic profiling solutions across Hungary and the Central and Eastern European region. Its expertise includes microbial composition analysis, CNV detection, mutation analysis, and methylation profiling, positioning the company as a trusted regional leader in NGS-driven genomic research.
Looking for a particular Astridbio Technologies employee's phone or email?
The Astridbio Technologies annual revenue was $4 million in 2026.
Robert Alfoldi is the CEO of Astridbio Technologies.
3 people are employed at Astridbio Technologies.
The NAICS codes for Astridbio Technologies are [54, 541, 54171, 5417, 541713].
The SIC codes for Astridbio Technologies are [87, 873].